XWELL Inc. - Asset Resilience Ratio
XWELL Inc. (XWEL) has an Asset Resilience Ratio of 0.06% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check XWEL capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how XWELL Inc.'s Asset Resilience Ratio has changed over time. See how leveraged is XWELL Inc.'s balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down XWELL Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see XWELL Inc. (XWEL) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.00K | 0.06% |
| Total Liquid Assets | $7.00K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: XWELL Inc. maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
XWELL Inc. Industry Peers by Asset Resilience Ratio
Compare XWELL Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for XWELL Inc. (2008–2025)
The table below shows the annual Asset Resilience Ratio data for XWELL Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.06% | $7.00K | $11.22 Million | -28.52pp |
| 2024-12-31 | 28.59% | $7.25 Million | $25.35 Million | -8.89pp |
| 2023-12-31 | 37.48% | $14.61 Million | $38.99 Million | +4.60pp |
| 2022-12-31 | 32.88% | $23.15 Million | $70.43 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $127.27 Million | -- |
| 2010-12-31 | 0.34% | $20.00K | $5.89 Million | -68.33pp |
| 2009-12-31 | 68.67% | $2.60 Million | $3.79 Million | +68.36pp |
| 2008-12-31 | 0.31% | $20.00K | $6.44 Million | -- |
About XWELL Inc.
XWELL, Inc. provides health and wellness services to travelers in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests to airport empl… Read more